rs2251780 — GSR

GSR rs2251780 — Glutathione Reductase and Cochlear Antioxidant Defense

Glutathione reductase (GSR) is the enzyme that closes the glutathione antioxidant cycle: it uses NADPH and the cofactor flavin adenine dinucleotide (FAD, derived from riboflavin/vitamin B2) to regenerate reduced glutathione (GSH) from oxidized glutathione (GSSG). Without functioning GSR, oxidative damage accumulates wherever GSH is the primary defense — including the highly metabolically active hair cells of the cochlea.

rs2251780 is an intronic variant in the GSR gene on chromosome 8 (8p12). The minor A allele is present in roughly 20% of the global population and has been classified as benign¹¹ benign
dbSNP ClinVar RCV001707149 by ClinVar with respect to general disease risk. Its functional effect, if any, is not yet characterized at the protein level.

The Mechanism

Glutathione reductase²² Glutathione reductase
FAD-dependent flavoenzyme that regenerates GSH from GSSG requires riboflavin-derived FAD as an obligate cofactor. Each GSR monomer contains one tightly bound FAD molecule. Riboflavin deficiency measurably reduces GSR activity in erythrocytes — a relationship so reliable that the erythrocyte glutathione reductase activation coefficient (EGRAC) is the clinical gold-standard biomarker for assessing riboflavin (vitamin B2) status. An EGRAC ≥ 1.3 indicates biochemical riboflavin deficiency.

Because rs2251780 sits in an intron, it does not alter the GSR amino acid sequence. Intronic variants can, however, influence gene expression via splicing regulation, transcription factor binding, or chromatin accessibility effects — none of which have been functionally demonstrated for this specific SNP. The association with hearing loss recovery is therefore a candidate-gene signal, not a mechanistic proof.

The Evidence

A prospective study by Kitoh, Nishio & Usami (2017)³³ Kitoh, Nishio & Usami (2017)
Prognostic impact of gene polymorphisms in patients with idiopathic sudden sensorineural hearing loss. Acta Otolaryngol, 2017 screened 16 SNPs across 13 antioxidant and vascular genes in 192 Japanese patients with sudden sensorineural hearing loss (SSNHL) receiving standardized corticosteroid therapy. GSR rs2251780 and a second GSR SNP (rs3779647) reached statistical significance (p<0.05) as predictors of poor hearing recovery. NOS3 rs1799983 (endothelial nitric oxide synthase) was co-associated. The study is small (n=192) and has not been independently replicated — evidence level is accordingly emerging.

A larger screen by Harris et al. (2007)⁴⁴ Harris et al. (2007)
A genetic association analysis of cognitive ability and cognitive ageing using 325 markers for 109 genes associated with oxidative stress or cognition. BMC Genetics, 2007 found no significant association between rs2251780 and any cognitive outcome across four cognitive tests in two independent cohorts (all p-values ≥0.23). This null result suggests the variant's phenotypic impact, if real, is narrow rather than a broad oxidative-stress signature.

Practical Actions

For AG or AA carriers, the primary practical lever is ensuring adequate riboflavin status, since GSR activity is directly coupled to FAD availability. Clinical riboflavin deficiency lowers measurable GSR activity, and supplementation restores it. Given the hearing-loss signal — even if preliminary — cochlear antioxidant reserve is the most plausible place this variant could matter.

Interactions

GSR rs2251780 was co-associated with NOS3 rs1799983 in the Kitoh 2017 hearing loss study, suggesting that combined impairment of cochlear antioxidant defense (GSR) and nitric oxide signaling (NOS3) may compound hearing vulnerability more than either variant alone. The mechanistic basis for this combination is plausible — both GSH and NO are reactive species whose cochlear balance is critical during acoustic trauma — but the combined effect has only been observed in one small study and requires replication before firm conclusions can be drawn.